Profile data is unavailable for this security.
About the company
GT Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of immuno-oncology products based on its Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. Its TriKE platform generates therapeutics designed to harness and enhance the cancer killing abilities of a patient’s own natural killer (NK) cells. The Company is also using its TriKE platform to develop therapeutics useful for the treatment of infectious disease such as for the treatment of patients infected by the human immunodeficiency virus (HIV). Its GTB-3550 is the first-generation TriKE product candidate which was a single-chain, tri-specific recombinant fusion protein construct composed of the variable regions of the heavy and light chains of anti-CD16 and anti-CD33 antibodies and a modified form of IL-15, all connected by small peptide linkers.
- Revenue in USD (TTM)0.00
- Net income in USD-9.64m
- Incorporated1973
- Employees2.00
- LocationGT Biopharma Inc8000 MARINA BLVD, SUITE 100BRISBANE 94005United StatesUSA
- Phone+1 (310) 551-4020
- Fax+1 (302) 655-5049
- Websitehttps://www.gtbiopharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hanyuan Biotech International Inc | 10.65m | 3.14m | 4.24m | -- | 0.0236 | 0.0051 | 1.16 | 0.3981 | 0.2246 | 0.2246 | 0.7611 | 1.03 | -- | -- | -- | -- | -- | -- | -- | -- | 68.54 | -- | 29.51 | -- | 13.36 | 25.66 | 0.00 | -- | 50.51 | -- | 106.71 | -- | -- | -- |
| Evoke Pharma Inc | 6.11m | -7.13m | 4.30m | 4.00 | -- | 1.23 | -- | 0.704 | -1.83 | -1.83 | 1.28 | 0.4068 | 0.5429 | 0.5113 | 5.71 | 1,526,428.00 | -63.39 | -100.48 | -76.67 | -151.10 | 96.01 | -- | -116.76 | -480.52 | 5.35 | -19.25 | 0.5884 | -- | 106.51 | -- | 5.25 | -- | -- | -- |
| Sonnet Biotherapeutics Holdings Inc | 92.74k | -8.43m | 4.47m | 12.00 | -- | 0.8727 | -- | 48.19 | -5.28 | -5.28 | 0.0315 | 0.9813 | 0.0097 | -- | 0.2248 | 7,728.33 | -87.68 | -- | -194.11 | -- | -- | -- | -9,086.22 | -- | -- | -138.21 | 0.00 | -- | -57.76 | -- | 36.64 | -- | -- | -- |
| Processa Pharmaceuticals Inc | 0.00 | -9.83m | 4.86m | 13.00 | -- | 0.5466 | -- | -- | -6.29 | -6.29 | 0.00 | 3.11 | 0.00 | -- | -- | 0.00 | -87.82 | -84.35 | -102.32 | -90.03 | -- | -- | -- | -- | -- | -- | 0.0012 | -- | -- | -- | 59.45 | -- | -34.05 | -- |
| Titan Pharmaceuticals Inc | 87.00k | -4.95m | 5.22m | 4.00 | -- | 0.8569 | -- | 59.94 | -6.41 | -6.41 | 0.1119 | 6.66 | 0.0197 | -- | 1.23 | 21,750.00 | -112.41 | -96.80 | -170.59 | -156.65 | -- | -- | -5,694.25 | -406.26 | -- | -415.19 | 0.00 | -- | -66.97 | -51.16 | 45.43 | -- | -65.61 | -- |
| Stemtech Corp | 5.17m | -4.61m | 5.79m | 45.00 | -- | -- | -- | 1.12 | -0.0482 | -0.0482 | 0.0543 | -0.0319 | 1.27 | 13.23 | 80.02 | -- | -113.00 | -- | -- | -- | 78.68 | -- | -89.26 | -- | 0.0563 | -4.06 | -- | -- | 7.94 | -- | 36.45 | -- | -- | -- |
| Sonoma Pharmaceuticals Inc | 12.74m | -4.84m | 5.82m | 172.00 | -- | 0.7782 | -- | 0.4566 | -0.7237 | -0.7237 | 1.40 | 0.3932 | 0.8224 | 2.87 | 4.66 | 74,040.70 | -31.22 | -29.36 | -41.09 | -40.65 | 37.26 | 38.00 | -37.97 | -30.93 | 2.64 | -- | 0.05 | -- | -4.05 | -7.66 | 6.13 | -- | -29.84 | -- |
| GT Biopharma Inc | 0.00 | -9.64m | 5.91m | 2.00 | -- | 0.7123 | -- | -- | -7.04 | -7.04 | 0.00 | 3.85 | 0.00 | -- | -- | 0.00 | -64.24 | -205.36 | -90.39 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 63.62 | -- | -- | -- |
| Integrated BioPharma, Inc. | 50.57m | -116.00k | 6.02m | 141.00 | -- | 0.3183 | 28.40 | 0.119 | -0.0041 | -0.0041 | 1.67 | 0.6283 | 1.88 | 4.45 | 10.76 | 358,617.00 | -0.431 | 15.51 | -0.5698 | 27.94 | 7.09 | 12.09 | -0.2294 | 6.44 | 1.02 | -9.00 | 0.001 | -- | -9.91 | 3.00 | -101.35 | -- | -14.03 | -- |
| Sentient Brands Holdings Inc | 0.00 | -818.63k | 6.10m | 2.00 | -- | -- | -- | -- | -0.0145 | -0.0145 | 0.00 | -0.036 | 0.00 | 0.0188 | -- | 0.00 | -317.87 | -220.36 | -- | -- | -- | 41.81 | -- | -31,451.19 | 0.0354 | -2.27 | -- | -- | -73.68 | -- | 34.98 | -- | -- | -- |
| Biofrontera Inc | 33.25m | -23.09m | 6.26m | 85.00 | -- | -- | -- | 0.1883 | -12.47 | -12.47 | 16.84 | -0.3627 | 0.9995 | 2.50 | 5.75 | 391,200.00 | -69.40 | -- | -144.06 | -- | 48.99 | -- | -69.44 | -- | 0.944 | -3.55 | 4.63 | -- | 18.82 | -- | -3,045.47 | -- | -- | -- |
| Shuttle Pharmaceuticals Holdings Inc | 0.00 | -7.35m | 6.72m | 8.00 | -- | 2.44 | -- | -- | -0.4739 | -0.4739 | 0.00 | 0.1642 | 0.00 | -- | -- | 0.00 | -96.75 | -- | -119.37 | -- | -- | -- | -- | -- | -- | -5.28 | 0.2542 | -- | -- | -- | -112.71 | -- | -- | -- |
| Sunshine Biopharma Inc | 26.74m | -4.09m | 6.89m | 44.00 | -- | 0.0118 | -- | 0.2577 | -13.35 | -13.35 | 76.96 | 24.96 | 0.9081 | 3.13 | 11.58 | 607,722.50 | -13.88 | -101.52 | -17.99 | -137.04 | 33.15 | 35.47 | -15.29 | -165.33 | 3.23 | -- | 0.00 | -- | 454.42 | -- | 83.15 | -- | 110.99 | -- |
| Cannapharmarx Inc | 25.84k | -6.61m | 7.29m | 21.00 | -- | -- | -- | 282.02 | -0.0205 | -0.0205 | 0.00008 | -0.0425 | 0.0031 | -- | 0.4503 | 1,230.48 | -79.52 | -131.06 | -- | -- | -1,692.76 | -- | -25,598.30 | -- | 0.0033 | -0.1306 | -- | -- | -- | -- | 143.24 | -- | -- | -- |
Data as of Jul 29 2024. Currency figures normalised to GT Biopharma Inc's reporting currency: US Dollar USD
15.66%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Bristol Capital Advisors LLCas of 23 May 2024 | 190.00k | 8.81% |
| Armistice Capital LLCas of 26 Apr 2024 | 72.51k | 3.36% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 20.51k | 0.95% |
| BMO Asset Management Corp.as of 31 Mar 2024 | 19.87k | 0.92% |
| Geode Capital Management LLCas of 31 Mar 2024 | 11.18k | 0.52% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 10.13k | 0.47% |
| Wells Fargo Advisors Financial Network LLCas of 31 Mar 2024 | 10.01k | 0.46% |
| Tower Research Capital LLCas of 31 Mar 2024 | 2.30k | 0.11% |
| UBS Securities LLCas of 31 Mar 2024 | 1.02k | 0.05% |
| Morgan Stanley Smith Barney LLC (Investment Management)as of 31 Mar 2024 | 266.00 | 0.01% |
More ▼
Data from 31 Mar 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
